Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab Impact on Coronary Plaque in CAD
NCT04851769Phase 4Completed
- Sponsor
- Beijing An Zhen Hospital
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of alirocumab in coronary artery disease (CAD), hypercholesterolemia, sponsored by Beijing An Zhen Hospital. Started Mar 2019; status: completed.
02
Drugs
alirocumab
03
Conditions
coronary artery disease (CAD)hypercholesterolemia
Beyond the preview
Go deeper on NCT04851769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851769.